Why the EMvision (ASX: EMV) share price closed 13% higher today

The EMvision (ASX: EMV) share price finished 13% higher today after the company announced grant success. Here's the rundown.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The EMvision Medical Devices Ltd (ASX: EMV) share price closed 13.2% higher today after the company made a funding announcement.

The EMvision share price finished off the trading session at $2.74 this afternoon.

Here's a wrap of where the funding will come from for the medical imaging technology provider, and why it may have moved the share price.

Rising healthcare ASX share price represented by doctor giving thumbs up

Image source: Getty Images

Australian Stroke Alliance wins bid

In today's release, EMvision advised that its commercial collaboration partner, the Australian Stroke Alliance (ASA), submitted a successful bid to the Stage 2 Medical Research Future Fund (MRFF) for a 5-year program to transform pre-hospital stroke care. 

The MRFF stage 2 program was awarded $100 million from the federal government, with 40 million allocated to ASA. 

Of the $40 million, ASA has advised EMVision that it will receive "$8 million of this non-dilutive cash funding in staged payments weighted to the earlier years of the program". 

This poses the opportunity for EMvision to commercialise its medical imaging technology and work toward further developments.

Executive commentary on funding

Commenting on the ASA collaboration, EMvision CEO Dr Ron Weinberger said:

The ASA brings together an end-to-end medical program to save and improve the lives of patients of one of the most debilitating medical emergencies in the world. No such consortium exists internationally, and the ASA will become a template for not only managing stroke, but other medical emergencies.

The ASA leadership has worked tirelessly to put Australia centre stage in this global battle to save healthy lives and is to be congratulated. We are grateful to the Australian government for recognising this vision and awarding one of the largest medical research grants in Australian history.

ASA co-chief investigator and neurologist, Professor Geoffrey Donnan, added:

We are excited to be commencing this ground-breaking research program. Lightweight portable and affordable brain imaging is the next frontier in stroke care…"

EMvision share price snapshot

Despite falling 22.4% year-to-date, the EMvision share price has gained 20.1% over the previous 6-month period.

The company's market capitalisation is approximately $171.2 million, and 70.8 million shares are outstanding.

Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of EMvision Medical Devices Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

a man weraing a suit sits nervously at his laptop computer biting into his clenched hand with nerves, and perhaps fear.
Share Fallers

Why Brightstar, EQ Resources, Novonix, and Pro Medicus shares are falling today

These shares are under pressure on hump day. But why?

Read more »

A happy family of four on holidays stand on a jetty and cheer.
Broker Notes

Down 40% in 2026, should you buy the big dip in Life360 shares?

A leading analyst offers his outlook for Life360 shares.

Read more »

Buy and sell on yellow paper with pins on them and several share price lines.
Broker Notes

Sell alert! Why this expert is calling time on Nuix and Brainchip shares

A leading analyst forecasts more pain to come for Brainchip and Nuix shares. But why?

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Share Gainers

Why EOS, Humm, New Hope, and Sims shares are storming higher today

These shares are having a good session on hump day. But why?

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »

Wife and husband with a laptop on a sofa over the moon at good news.
Healthcare Shares

Why are Telix shares racing 8% higher today?

Telix shares are now 11% higher for the year-to-date.

Read more »

Magnifying glass on a rising interest rate graph.
Share Market News

Buying ASX shares or paying off a mortgage? Here's what the experts are saying about RBA interest rate hikes in 2026

Leading experts sound off on the RBA’s latest interest rate hike, and what investors and mortgage holders can expect next.

Read more »

Focused man entrepreneur with glasses working, looking at laptop screen thinking about something intently while sitting in the office.
Broker Notes

Buy, hold, sell: Clarity Pharmaceuticals, New Hope, and Orica shares

Brokers have been looking at these shares this week. Are they bullish?

Read more »